Drug Discovery Outsourcing Market Share Analysis Report, 2023-2032
The global drug discovery outsourcing market size was exhibited at USD 4.2 billion in 2022 and is projected to hit around USD 8.91 billion by 2032, growing at a CAGR of 7.8% during the forecast period 2023 to 2032.
Key Pointers:
Drug discovery outsourcing Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 4.53 Billion |
|
Market Size by 2032 |
USD 8.91 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 7.8% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Workflow, therapeutics area, drug type, type, end-user and region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Key companies profiled |
Albany Molecular Research Inc.; EVOTEC; Laboratory Corporation of America Holdings; GenScript; Pharmaceutical Product Development, LLC; Charles River; WuXi AppTec; Merck & Co., Inc.; Thermo Fisher Scientific Inc.; Dalton Pharma Services; Oncodesign; Jubilant Biosys; DiscoverX Corp.; QIAGEN; Eurofins SE, Syngene International Limited, Dr. Reddy Laboratories Ltd., Pharmaron Beijing Co., Ltd., TCG Lifesciences Pvt Ltd., Domainex Ltd. |
According to a survey conducted by Life Science Strategy Group of 120 clinical development decision-makers in the U. S., Europe, and China, industry professionals are undertaking major strategic changes to maintain their share in the unpredictable market scenario post the COVID-19 pandemic. The pharmaceutical industry has witnessed radical changes in the past two decades, in terms of a shift toward biologics, patent expiration, and unprecedented downsizing of internal discovery of big pharmaceuticals. All of this has accelerated the adoption of outsourcing activities.
Breaking down the different steps of drug discovery, such as hit confirmation, lead generation, lead optimization, and high-speed screening allows players to specialize in their core services. An estimated 75.0% to 80.0% of R&D spending in the biopharmaceutical industry can be outsourced, creating opportunities for Contract Research Organizations (CROs), which, in turn, is expected to boost the market growth. Pharmaceutical companies are partnering with manufacturing facilities in developing countries, which are backed by skilled manpower, low cost, and quality data. Cost-cutting, chasing innovation, gaining access to specialized knowledge and technology, and increasing speed and agility are some of the significant factors encouraging pharma companies to expand the level of outsourcing.
This, in return, is expected to increase competition among key players, leading to the emergence of various new startups across the hotspot regions, such as the U.S., China, India, South Korea, Singapore, and other southeast Asian countries. For instance, in July 2018, Syngene International Ltd., a leading CRO based in India, extended its R&D collaboration with Baxter Healthcare Corporation until 2024. In March 2018, the company formed a multi-year agreement with GlaxoSmithKline (GSK) to accelerate the discovery of new drug candidates. The COVID-19 pandemic has slowed down various drug discovery processes due to the halting of various clinical trials.
However, on a brighter note, generous incentives are expected for pharmaceutical companies to invest in developing Infectious Diseases (ID) drugs and vaccines. Public health challenges in oncology, heart disease, and many other rare conditions still exist. For these, clinical research must go on. Here, CROs are expected to utilize their creativity to the fullest. With an urgent need for an effective vaccine/drug, companies are increasingly opting for outsourcing to enhance their clinical trials, which is expected to boost market growth for several years.
Workflow Insights
Lead identification & candidate optimization dominated the workflow segment with a revenue share of more than 33.00% in 2022. Based on workflows, the market is segmented into target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and other associated workflows. The iterative process of lead identification, also known as hit-to-lead, is a significant stage in early drug discovery. It has historically proven to have improved efficiencies and economies of scale for drug developers. The introduction of advanced in silico techniques to improve the lead identification process, such as Computer-Aided Drug Discovery (CADD) and structure-based drug designs, support segment growth.
The rising need for skilled resources with combinational knowledge of metabolism, analytical chemistry, and computer software, along with the high cost associated with the integration of the latest computation technology, is enabling higher outsourcing for lead identification services. As a result, lead identification and candidate optimization accounted for the largest share, in terms of revenue in 2022. The other associated services segment, which includes cell line development, upstream & downstream processes, analytical/bioanalytical methods, formulations & quality assessment, and regulatory assistance, is anticipated to witness rapid growth in the coming years. This is owing to the increased adoption of outsourcing services and high investments in drug discovery R&D.
Therapeutics Area Insights
The respiratory systems segment accounted for the largest share of over 14.9% of the global revenue in 2022. Based on therapeutic areas, the market is segmented into the respiratory system, pain and anesthesiaoncology, ophthalmology, hematology, cardiovascular, endocrine, gastrointestinal, immunomodulation, anti-infective, central nervous system, dermatology, and genitourinary system. High incidence of respiratory disorders, such as bronchitis, tuberculosis, Chronic Obstructive Pulmonary Diseases (COPD), and asthma, coupled with increasing cases of drug resistance, has influenced the segment growth.
Furthermore, the introduction of novel drug delivery technologies, such as nasal sprays, has been identified to be the key contributor to the segment revenue. Lung diseases are responsible for over 700,000 hospital admissions and over 6 million inpatient bed-days in the U.K. per year. An estimated 1.2 million people are living with diagnosed COPD in the U.K. In view of this, in 2018, The University of Nottingham formed a strategic research collaboration with GSK and the University of Leicester.The collaboration is aimed at accelerating the discovery and development of innovative treatments for COPD. The oncology and anti-infective segments are both projected to witness significant CAGRs over the forecast period.
Increased focus on the identification of novel targets to support cancer treatment contributes to the lucrative growth of the oncology segment.In June 2020, AstraZeneca collaborated with Accent Therapeutics to discover, develop and commercialize transformative therapeutics targeting RNA-Modifying Proteins (RMPs) for the treatment of cancer. Accent will be responsible for R&D activities for a nominated preclinical program through to the end of Phase I clinical trials. Antimicrobial resistance is projected to become a global crisis with its soaring rate of emergence and spread resulting in a high economic burden. Companies have increased R&D in anti-infective drugs, having identified the future need. This is poised to benefit the market growth.
Drug Type Insights
The small molecules/pharmaceuticals segment accounted for the largest share of over 78.3% in 2022 and is projected to expand further at the fastest CAGR during the forecast period. Based on drug types, the market is classified into small and large molecules. Small molecules play a significant role in the development of innovative treatments for patients worldwide. Sales of half of the specialty medicines are attributable to small molecule applications. Its role is also visible in the recent approval trends. In 2019, the FDA approved 48 new drugs, 79% of which were composed of small molecules. Small molecules continue to play a vital role in the innovation of treatments across four key therapeutic areas: oncology, cardiovascular, autoimmune, and respiratory diseases.
Increased significance and highly effective components add up to the potential of small molecules in the pharmaceutical portfolio. Owing to this, the small molecules segment held the largest share in the market. Furthermore, the advantages of small molecules over larger ones have increased investments in the field, especially in cancer research. Small molecules can be administered orally, especially for the treatment of chronic diseases, they are cheaper, easy to manufacture, and can be combined with intracellular targets. Ongoing studies to investigate and develop novel therapeutics for various indications are expected to further influence segment growth.
Regional Insights
North America dominated the market in 2022 and accounted for the largest share of more than 36.8% of the global revenue. The growth of the regional market can be attributed to the technological advancements, presence of well-established research infrastructure & key players, and higher investments in drug discovery R&D. With outsourcing no longer being solely about cost reduction, rising need for efficiency, quality, and innovation are expected to contribute to market growth.The Asia region is projected to register the fastest CAGR during the forecast period. The region is emerging as a hub for outsourcing drug discovery activities owing to the availability of skilled manpower, lower costs, favorable regulatory environment, and quality data.
Japan, being the second-largest pharmaceutical market at a global level, is expected to provide a robust opportunity for CROs, thus driving the market. The revised Pharmaceutical Affairs Law supports research activities regarding tissue diagnostics and cancer in Japan, which is expected to boost the market growth in this country. In 2015, the Japan Agency for Medical Research and Development (AMED) was established with an objective to manage data related to investigations and clinical trials, improve R&D infrastructure, and promote international strategies. This agency is an example of the initiatives taken to boost the market growth in Japan.
Some of the prominent players in the Drug discovery outsourcing Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global drug discovery outsourcing market.
By Workflow
By Therapeutics Area
By Drug Type
By Type
By End-User
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Workflow
1.1.2. Therapeutic Area
1.1.3. Drug type
1.1.4. Type
1.1.5. End-user
1.1.6. Regional scope
1.1.7. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Nova one advisor’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Workflow outlook
2.2.2. Therapeutic area outlook
2.2.3. Drug type outlook
2.2.4. Type outlook
2.2.5. End-user outlook
2.2.6. Regional outlook
2.3. Competitive Insights
Chapter 3. Drug Discovery Outsourcing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.3.3. Industry challenges
3.4. Drug Discovery Outsourcing Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
3.4.3. Major Deals & Strategic Alliances Analysis
3.4.4. Market Entry Strategies
3.4.5. Covid Impact Analysis
Chapter 4. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Target Identification & Screening
4.1.2. Target Validation & Functional Informatics
4.1.3. Lead Identification & Candidate Optimization
4.1.4. Preclinical Development
4.1.5. Other Associate Workflow
4.2. Drug Discovery Outsourcing Market Share, 2023 & 2032
4.3. Segment Dashboard
4.4. Global Drug Discovery Market by Workflow Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2020 to 2032 for the following
4.5.1. Target Identification & Screening
4.5.1.1. Target Identification & Screening market estimates and forecast 2020 to 2032
4.5.2. Target Validation & Functional Informatics
4.5.2.1. Target Validation & Functional Informatics Market estimates and forecast 2020 to 2032
4.5.3. Lead Identification & Candidate Optimization
4.5.3.1. Lead Identification & Candidate Optimization Market estimates and forecast 2020 to 2032
4.5.4. Preclinical Development
4.5.4.1. Preclinical Development Market estimates and forecast 2020 to 2032
4.5.5. Other Associate Workflow
4.5.5.1. Other Associate Workflow Market estimates and forecast 2020 to 2032
Chapter 5. Drug Discovery Outsourcing Market: Therapeutic Area Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Respiratory System
5.1.2. Pain and Anesthesia
5.1.3. Oncology
5.1.4. Ophthalmology
5.1.5. Hematology
5.1.6. Cardiovascular
5.1.7. Endocrine
5.1.8. Gastrointestinal
5.1.9. Immunomodulation
5.1.10. Anti-infective
5.1.11. Central Nervous System
5.1.12. Dermatology
5.1.13. Genitourinary System
5.2. Drug Discovery Outsourcing Market Share, 2023 & 2032
5.3. Segment Dashboard
5.4. Global Drug Discovery Outsourcing Market by Drug Type Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2020 to 2032 for the following
5.5.1. Respiratory System
5.5.1.1. Respiratory System market estimates and forecast 2020 to 2032
5.5.2. Pain and Anesthesia
5.5.2.1. Pain and Anesthesia market estimates and forecast 2020 to 2032
5.5.3. Oncology
5.5.3.1. Oncology market estimates and forecast 2020 to 2032
5.5.4. Ophthalmology
5.5.4.1. Ophthalmology market estimates and forecast 2020 to 2032
5.5.5. Hematology
5.5.5.1. Hematology market estimates and forecast 2020 to 2032
5.5.6. Cardiovascular
5.5.6.1. Cardiovascular market estimates and forecast 2020 to 2032
5.5.7. Endocrine
5.5.7.1. Endocrine market estimates and forecast 2020 to 2032
5.5.8. Gastrointestinal
5.5.8.1. Gastrointestinal market estimates and forecast 2020 to 2032
5.5.9. Immunomodulation
5.5.9.1. Immunomodulation market estimates and forecast 2020 to 2032
5.5.10. Anti-infective
5.5.10.1. Anti-infective market estimates and forecast 2020 to 2032
5.5.11. Central Nervous System
5.5.11.1. Central Nervous System market estimates and forecast 2020 to 2032
5.5.12. Dermatology
5.5.12.1. Dermatology market estimates and forecast 2020 to 2032
5.5.13. Genitourinary System
5.5.13.1. Genitourinary System market estimates and forecast 2020 to 2032
Chapter 6. Drug Discovery Outsourcing Market: Drug Type Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Chemistry Services
6.1.2. Biology Services
6.2. Drug Discovery Outsourcing Market Share, 2023 & 2032
6.3. Segment Dashboard
6.4. Global Drug Discovery Market by Drug Type Outlook
6.5. Market Size & Forecasts and Trend Analyses, 2020 to 2032 for the following
6.5.1. Small Molecule
6.5.1.1. Small Molecule Market estimates and forecast 2020 to 2032
6.5.2. Large Molecule
6.5.2.1. Large Molecule Market estimates and forecast 2020 to 2032
Chapter 7. Drug Discovery Outsourcing Market: Type Estimates & Trend Analysis
7.1. Definitions and Scope
7.1.1. Chemistry Services
7.1.2. Biology Services
7.2. Drug Discovery Outsourcing Market Share, 2023 & 2032
7.3. Segment Dashboard
7.4. Global Drug Discovery Market by Type Outlook
7.5. Market Size & Forecasts and Trend Analyses, 2020 to 2032 for the following
7.5.1. Chemistry Services
7.5.1.1. Chemistry Services market estimates and forecast 2020 to 2032
7.5.2. Biology Services
7.5.2.1. Biology Services Market estimates and forecast 2020 to 2032
Chapter 8. Drug Discovery Outsourcing Market: End-user Estimates & Trend Analysis
8.1. Definitions and Scope
8.1.1. Pharmaceutical & Biotechnology Companies
8.1.2. Academic Institutes
8.1.3. Others
8.2. Drug Discovery Outsourcing Market Share, 2023 & 2032
8.3. Segment Dashboard
8.4. Global Drug Discovery Market by End-user Outlook
8.5. Market Size & Forecasts and Trend Analyses, 2020 to 2032 for the following
8.5.1. Pharmaceutical & Biotechnology Companies
8.5.1.1. Pharmaceutical & Biotechnology Companies market estimates and forecast 2020 to 2032
8.5.2. Academic Institutes
8.5.2.1. Academic Institutes Market estimates and forecast 2020 to 2032
8.5.3. Others
8.5.3.1. Others Market estimates and forecast 2020 to 2032
Chapter 9. Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis
9.1. Regional market share analysis, 2023 & 2032
9.2. Regional Market Dashboard
9.3. Global Regional Market Snapshot
9.4. Regional Market Share and Leading Players, 2023
9.4.1. North America
9.4.2. Europe
9.4.3. Asia Pacific
9.4.4. Latin America
9.4.5. Middle East and Africa
9.5. Market Size, & Forecasts, Volume and Trend Analysis, 2020 to 2032:
9.6. North America
9.6.1. Market estimates and forecast, 2020 - 2032 (Value)
9.6.2. U.S.
9.6.2.1. Market estimates and forecast, 2020 - 2032
9.6.3. Canada
9.6.3.1. Market estimates and forecast, 2020 - 2032
9.7. Europe
9.7.1. UK
9.7.1.1. Market estimates and forecast, 2020 - 2032
9.7.2. Germany
9.7.2.1. Market estimates and forecast, 2020 - 2032
9.7.3. France
9.7.3.1. Market estimates and forecast, 2020 - 2032
9.7.4. Italy
9.7.4.1. Market estimates and forecast, 2020 - 2032
9.7.5. Spain
9.7.5.1. Market estimates and forecast, 2020 - 2032
9.7.6. Netherland
9.7.6.1. Market estimates and forecast, 2020 - 2032
9.7.7. Belgium
9.7.7.1. Market estimates and forecast, 2020 - 2032
9.7.8. Switzerland
9.7.8.1. Market estimates and forecast, 2020 - 2032
9.7.9. Russia
9.7.9.1. Market estimates and forecast, 2020 - 2032
9.7.10. Sweden
9.7.10.1. Market estimates and forecast, 2020 - 2032
9.8. Asia Pacific
9.8.1. Japan
9.8.1.1. Market estimates and forecast, 2020 - 2032
9.8.2. China
9.8.2.1. Market estimates and forecast, 2020 - 2032
9.8.3. India
9.8.3.1. Market estimates and forecast, 2020 - 2032
9.8.4. Thailand
9.8.4.1. Market estimates and forecast, 2020 - 2032
9.8.5. South Korea
9.8.5.1. Market estimates and forecast, 2020 - 2032
9.8.6. Australia
9.8.6.1. Market estimates and forecast, 2020 - 2032
9.8.7. Malaysia
9.8.7.1. Market estimates and forecast, 2020 - 2032
9.8.8. Indonesia
9.8.8.1. Market estimates and forecast, 2020 - 2032
9.8.9. Singapore
9.8.9.1. Market estimates and forecast, 2020 - 2032
9.8.10. Philippines
9.8.10.1. Market estimates and forecast, 2020 - 2032
9.8.11. Thailand
9.8.11.1. Market estimates and forecast, 2020 - 2032
9.9. Latin America
9.9.1. Brazil
9.9.1.1. Market estimates and forecast, 2020 - 2032
9.9.2. Mexico
9.9.2.1. Market estimates and forecast, 2020 - 2032
9.9.3. Argentina
9.9.3.1. Market estimates and forecast, 2020 - 2032
9.9.4. Colombia
9.9.4.1. Market estimates and forecast, 2020 - 2032
9.9.5. Chile
9.9.5.1. Market estimates and forecast, 2020 - 2032
9.10. MEA
9.10.1. South Africa
9.10.1.1. Market estimates and forecast, 2020 - 2032
9.10.2. Saudi Arabia
9.10.2.1. Market estimates and forecast, 2020 - 2032
9.10.3. UAE
9.10.3.1. Market estimates and forecast, 2020 - 2032
9.10.4. Israel
9.10.4.1. Market estimates and forecast, 2020 - 2032
9.10.5. Egypt
9.10.5.1. Market estimates and forecast, 2020 - 2032
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.1.1. Albany Molecular Research Inc.
10.1.1.1. Company overview
10.1.1.2. Product benchmarking
10.1.1.3. Strategic initiatives
10.1.2. EVOTEC
10.1.2.1. Company overview
10.1.2.2. Financial performance
10.1.2.3. Product benchmarking
10.1.2.4. Strategic initiatives
10.1.3. Laboratory Corporation of American Holdings
10.1.3.1. Company overview
10.1.3.2. Financial performance
10.1.3.3. Product benchmarking
10.1.3.4. Strategic initiatives
10.1.4. GenScript
10.1.4.1. Company overview
10.1.4.2. Financial performance
10.1.4.3. Product benchmarking
10.1.4.4. Strategic initiatives
10.1.5. Pharmaceutical Product Development LLC
10.1.5.1. Company overview
10.1.5.2. Financial performance
10.1.5.3. Product benchmarking
10.1.5.4. Strategic initiatives
10.1.6. Charles River Laboratory
10.1.6.1. Company overview
10.1.6.2. Financial performance
10.1.6.3. Product benchmarking
10.1.6.4. Strategic initiatives
10.1.7. Wuxi AppTec
10.1.7.1. Company overview
10.1.7.2. Financial performance
10.1.7.3. Product benchmarking
10.1.7.4. Strategic initiatives
10.1.8. Merck & Co. Inc.
10.1.8.1. Company overview
10.1.8.2. Financial performance
10.1.8.3. Product benchmarking
10.1.8.4. Strategic initiatives
10.1.9. Thermos Fisher Scientific Inc.
10.1.9.1. Company overview
10.1.9.2. Financial performance
10.1.9.3. Product benchmarking
10.1.9.4. Strategic initiatives
10.1.10. Dalton Pharma Services
10.1.10.1. Company overview
10.1.10.2. Financial performance
10.1.10.3. Product benchmarking
10.1.10.4. Strategic initiatives
10.1.11. Oncodesign
10.1.11.1. Company overview
10.1.11.2. Financial performance
10.1.11.3. Product benchmarking
10.1.11.4. Strategic initiatives
10.1.12. Jubilant Biosys
10.1.12.1. Company overview
10.1.12.2. Financial performance
10.1.12.3. Product benchmarking
10.1.12.4. Strategic initiatives
10.1.13. DiscoverX. Corp.
10.1.13.1. Company overview
10.1.13.2. Financial performance
10.1.13.3. Product benchmarking
10.1.13.4. Strategic initiatives
10.1.14. QIAGEN
10.1.14.1. Company overview
10.1.14.2. Financial performance
10.1.14.3. Product benchmarking
10.1.14.4. Strategic initiatives
10.1.15. Eurofins SE
10.1.15.1. Company overview
10.1.15.2. Financial performance
10.1.15.3. Product benchmarking
10.1.15.4. Strategic initiatives
10.1.16. Syngene International Limited
10.1.16.1. Company overview
10.1.16.2. Financial performance
10.1.16.3. Product benchmarking
10.1.16.4. Strategic initiatives
10.1.17. Dr. Reddy Laboratories Ltd.
10.1.17.1. Company overview
10.1.17.2. Financial performance
10.1.17.3. Product benchmarking
10.1.17.4. Strategic initiatives
10.1.18. Pharmaron Beijing Co., Ltd.
10.1.18.1. Company overview
10.1.18.2. Financial performance
10.1.18.3. Product benchmarking
10.1.18.4. Strategic initiatives
10.1.19. TCG Lifesciences Pvt Ltd.
10.1.19.1. Company overview
10.1.19.2. Financial performance
10.1.19.3. Product benchmarking
10.1.19.4. Strategic initiatives
10.1.20. Domainex Ltd.
10.1.20.1. Company overview
10.1.20.2. Financial performance
10.1.20.3. Product benchmarking
10.1.20.4. Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers